Business
Appointment of Joint Broker
Appointment of Joint Broker.
About this update from Hvivo Plc
[{"type":"text","content":"\n \n \n RNS Number : 3645M\n Open Orphan PLC\n 11 May 2020\n \n \n \n \n Open Orphan plc\n \n \n (\"Open Orphan\" or the \"Company\")\n \n \n Appointment of Joint Broker\n \n \n \n \n Open Orphan plc (AIM: ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, announces the appointment of finnCap Ltd as its joint broker with immediate effect.\n \n \n \n \n \n \n \n \n \n \n \n Open Orphan plc\n \n \n \n \n \n \n \n \n \n \n \n \n \n Cathal Friel, Executive Chairman\n \n \n \n \n +353 (0)1 644 0007\n \n \n \n \n \n \n Arden Partners plc (Nominated Adviser and Joint Broker)\n \n \n \n \n +44 (0)20 7614 5900\n \n \n \n \n \n \n John Llewellyn-Lloyd / Benjamin Cryer \n \n \n \n \n \n \n \n \n \n \n \n \n \n finnCap Ltd (Joint Broker)\n \n \n \n \n +44 (0)20 7220 0500\n \n \n \n \n \n \n Geoff Nash /James Thompson/Richard Chambers \n \n \n \n \n \n \n \n \n \n \n \n \n \n Davy (Euronext Growth Adviser and Joint Broker)\n \n \n \n \n +353 (0)1 679 6363\n \n \n \n \n \n \n Anthony Farrell\n \n \n \n \n \n \n \n \n \n \n \n \n \n Camarco (Financial PR)\n \n \n \n \n +44 (0)20 3757 4980\n \n \n \n \n \n \n Tom Huddart / Hugo Liddy\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Notes to Editors:\n \n \n Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. It has Europe's only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London. hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of Covid-19 in 2020. The Company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a Coronavirus challenge study model and expects to be very active with many companies in the development of a Covid-19 vaccine. No other compan...